effects of pomegranate juice consumption in inflammatory factors( hs-CRP; ICAM; VCAM; IL-6; E-Selectin ) and blood pressure and endothelial function evaluation (FMD) in hypertensive patients

Not Applicable

• Conditions: Condition 1: Blood pressure. Condition 2: flow-mediated dilatation (FMD).; Hypertensive diseases; Diseases of arteries, arterioles and capillaries; I10-I15; I70-I79

• Registration Number: IRCT201206249662N4
• Lead Sponsor: Isfahan Cardiovascular Research Center

Brief Summary

Pomegranate (Punica granatum L.) juice (PJ) contains different types of antioxidants and bioactive polyphenols<br /> and has been reported to promote cardiovascular health through several mechanisms. The present study aimed<br /> to examine the effects of 2-week intake of fresh PJ on blood pressure, flow-mediated dilatation (FMD), serum<br /> lipid profile and concentrations of inflammatory and endothelial function biomarkers. Twenty-one hypertensive<br /> patients (aged 30–67 years) were recruited into the trial and assigned to receive either PJ (150 ml/day in a single<br /> occasion between lunch and dinner; n = 11) or the same amount of water (n = 10) for a period of 2 weeks. Systolic<br /> (SBP) and diastolic (DBP) pressures together with FMD and serum concentrations of lipid profile parameters,<br /> apolipoproteins A and B, intracellular adhesion molecule-1 (ICAM-1), vascular endothelial adhesion molecule<br /> 1 (VCAM-1), E-selectin, high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) were measured<br /> at baseline and at the end of trial. PJ consumption was associated with significant reductions in SBP<br /> (p = 0.002) and DBP (p = 0.038) but not FMD (p>0.05). Serum levels of VCAM-1 (p = 0.008) were significantly<br /> reduced by PJ while those of E-selectin were elevated (p = 0.039). However, no significant effect was observed<br /> from PJ on serum levels of ICAM-1, hs-CRP, lipid profile parameters, apolipoproteins and IL-6 in any of the<br /> study groups (p>0.05). Consumption of PJ for 2 weeks has effective hypotensive effects, and may improve<br /> endothelial function by decreasing serum concentrations of VCAM-1. These findings suggest PJ as a beneficial<br /> cardioprotective supplement for hypertensive subjects

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

hypertensive patients whit :BMI more than 18 and less than 35kg/m2 ; Systolic blood pressure (SBP) more than 100 and less than 160 mm Hg; Diastolic blood pressure (DBP) more than 50 and less than 100 mm Hg

Exclusion criteria: Individuals with a history of diseases; diabetes; cardiovascular disease; liver and kidney as well as those with thyroid disease; pregnant and breastfeeding; metabolic and endocrine diseases

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Positive changes in inflammatory markers. Timepoint: Baseline and after 2 weeks. Method of measurement: ELISA kit.;Positive changes in endothelial function. Timepoint: Baseline and after 2weeks. Method of measurement: Doppler ultrasonography.

Secondary Outcome Measures

Name	Time	Method
Blood pressure. Timepoint: Baseline and after 2 weeks. Method of measurement: Sphygmomanometer.;Positive changes in lipid profiles. Timepoint: Baseline and after 2 weeks. Method of measurement: kit.;Cholesterol Level. Timepoint: Before and after 2 weeks. Method of measurement: KIT.;HDL Level. Timepoint: Before and after 4 weeks. Method of measurement: KIT.;LDL level. Timepoint: Before and after 2weeks. Method of measurement: KIT.